# OnCo record nct06264180 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06264180/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06264180", "NCT06264180" ;
  schema:name "VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]"@en ;
  schema:description "A phase 3 trial of Vusolimogene oderparepvec, Nivolumab, Relatlimab + nivolumab and Pembrolizumab in Advanced melanoma, run by Replimune, Inc., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06264180/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06264180> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/advanced-melanoma/> ;
  onco:drugs <https://onco.cc/drugs/vusolimogene-oderparepvec/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/relatlimab-nivolumab/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/replimune/> .